Novocure Ltd (NVCR): Michael J. Ambrogi , Chief Operating Officer of Novocure Ltd sold 20,000 shares on Jun 8, 2016. The Insider selling transaction was reported by the company on Jun 10, 2016 to the Securities and Exchange Commission. The shares were sold at $12.24 per share for a total value of $244,800.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 4, 2016, Asaf Danziger (CEO) purchased 10,000 shares at $15.00 per share price.On Mar 4, 2016, Robert J Jr Mylod (director) purchased 20,000 shares at $15.78 per share price.
NovoCure Limited (NovoCure) is a commercial-stage oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. Its TTFields is an anti-mitotic treatment. It also focuses on the clinical trials for the use of TTFields in brain metastases advanced non-small cell lung cancer (NSCLC) pancreatic cancer ovarian cancer and mesothelioma. It is engaged in pipeline development for various indications such as recurrent glioblastoma diagnosed glioblastoma brain metastasis squamous non-small cell lung cancer ovarian cancer pancreatic cancer mesothelioma breast cancer cervical cancer colorectal carcinoma liver metastases malignant melanoma prostate cancer renal adenocarcinoma and urinary transitional cell carcinoma. It offers Optune a TTFields delivery system for use as a monotherapy treatment and NovoTTF-100L for NSCLC.